Related references
Note: Only part of the references are listed.Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases
Mahesh Chandra Patra et al.
SEMINARS IN CANCER BIOLOGY (2020)
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Kenji Chamoto et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Below the surface: The inner lives of TLR4 and TLR9
Laura Marongiu et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti -PD-1 therapy.
Marcus O. Butler et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches
Aaron J. Franke et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
M. Angela Aznar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
Kalijn F. Bol et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Durvalumab in cancer medicine: a comprehensive review
Juliana Alvarez-Argote et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect
Nathan Suek et al.
FRONTIERS IN IMMUNOLOGY (2019)
Trial watch: dendritic cell vaccination for cancer immunotherapy
Jenny Sprooten et al.
ONCOIMMUNOLOGY (2019)
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
Jean-Francois Rossi et al.
CANCER COMMUNICATIONS (2019)
Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales
Li Fan et al.
CANCER LETTERS (2019)
Emerging therapeutic agents for genitourinary cancers
Kevin Zarrabi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years
Randall N. Hyer et al.
VACCINE (2019)
Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors
Kerstin Kapp et al.
ONCOIMMUNOLOGY (2019)
Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity
Ondrej Uher et al.
SEMINARS IN ONCOLOGY (2019)
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Katsiaryna Marhelava et al.
CANCERS (2019)
Adoptive cellular therapies: the current landscape
Maartje W. Rohaan et al.
VIRCHOWS ARCHIV (2019)
The Intriguing History of Cancer Immunotherapy
Paula Dobosz et al.
FRONTIERS IN IMMUNOLOGY (2019)
Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Shailender Bhatia et al.
CLINICAL CANCER RESEARCH (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Roberta Zappasodi et al.
CANCER CELL (2018)
Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay
Marilena Gallotta et al.
CANCER RESEARCH (2018)
Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Vincenzo Cerullo et al.
CURRENT CANCER DRUG TARGETS (2018)
Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions
Catherine E. Handy et al.
FUTURE ONCOLOGY (2018)
Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer
Amir Mehrvarz Sarshekeh et al.
FUTURE ONCOLOGY (2018)
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma
Smita S. Joshi et al.
FUTURE ONCOLOGY (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
Caroline Pettenati et al.
NATURE REVIEWS UROLOGY (2018)
Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
Tsukasa Seya et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2018)
The revival of CpG oligonucleotide-based cancer immunotherapies
Tomasz Adamus et al.
Wspolczesna Onkologia-Contemporary Oncology (2018)
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Debra L. Madden
CURRENT ONCOLOGY REPORTS (2018)
Warming Cold Melanoma with TLR9 Agonists
Alissa Poh
CANCER DISCOVERY (2018)
Talimogene laherparepvec: First in class oncolytic virotherapy
Robert M. Conry et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Further Advances in Cancer immunotherapy: Going Beyond Checkpoint Blockade
Robert W. Wilkinson et al.
FRONTIERS IN IMMUNOLOGY (2018)
Recognition of Double-Stranded RNA and Regulation of Interferon Pathway by Toll-Like Receptor 10
Suki Man-Yan Lee et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers
Vinay Prasad et al.
JAMA ONCOLOGY (2018)
Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
Merly Contratto et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
A Review on Imiquimod Therapy and Discussion on Optimal Management of Basal Cell Carcinomas
Preetha Kamath et al.
CLINICAL DRUG INVESTIGATION (2018)
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
Xin Gao et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Antoni Ribas et al.
CANCER DISCOVERY (2018)
Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies
Dora Hammerl et al.
TRENDS IN IMMUNOLOGY (2018)
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Melody Smith et al.
ONCOIMMUNOLOGY (2018)
The interaction between IKKα and LC3 promotes type I interferon production through the TLR9-containing LAPosome
Kachiko Hayashi et al.
SCIENCE SIGNALING (2018)
A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer
C. P. Belani et al.
ANNALS OF ONCOLOGY (2017)
Immunotherapy of cancers comes of age
Hila Yousefi et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells
Sarang Tartey et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2017)
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Erin Larkins et al.
ONCOLOGIST (2017)
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
Vinay Prasad et al.
SEMINARS IN ONCOLOGY (2017)
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Anna Passarelli et al.
ONCOTARGET (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation
Chao-Yang Lai et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer
Fumi Sato-Kaneko et al.
JCI INSIGHT (2017)
Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges
Yael Diesendruck et al.
DRUG RESISTANCE UPDATES (2017)
Cancer immunotherapies targeting the PD-1 signaling pathway
Yoshiko Iwai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Dendritic cells in cancer: the role revisited
Filippo Veglia et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Kristina Iribarren et al.
ONCOIMMUNOLOGY (2016)
Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia
Qifang Zhang et al.
BLOOD (2016)
Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Daniela Cerezo-Wallis et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Imiquimod in dermatology: an overview
Edith Hanna et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2016)
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
Joohee Sul et al.
ONCOLOGIST (2016)
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells
Shu Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Intracellular osteopontin stabilizes TRAF3 to positively regulate innate antiviral response
Kai Zhao et al.
SCIENTIFIC REPORTS (2016)
Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease
Xuetao Cao
NATURE REVIEWS IMMUNOLOGY (2016)
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
B. Homet Moreno et al.
BRITISH JOURNAL OF CANCER (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703
Manuel Schmidt et al.
NUCLEIC ACID THERAPEUTICS (2015)
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
Jennifer Kleponis et al.
CANCER BIOLOGY & MEDICINE (2015)
Modes of action of TLR7 agonists in cancer therapy
Sebastian Kobold et al.
IMMUNOTHERAPY (2014)
Development of CpG-Oligodeoxynucleotides for Effective Activation of Rabbit TLR9 Mediated Immune Responses
Tsung-Hsien Chuang et al.
PLOS ONE (2014)
Push and release TLR9 activation plus STAT3 blockade for systemic antitumor immunity
Marcin Kortylewski et al.
ONCOIMMUNOLOGY (2014)
Toll-Like Receptor 9 Agonists for Cancer Therapy
Davide Melisi et al.
BIOMEDICINES (2014)
Pattern recognition receptors in innate immunity, host defense, and immunopathology
Rahul Suresh et al.
ADVANCES IN PHYSIOLOGY EDUCATION (2013)
TLR2 & Co: a critical analysis of the complex interactions between TLR2 and coreceptors
Jeroen van Bergenhenegouwen et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
C. Manegold et al.
ANNALS OF ONCOLOGY (2012)
Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
Nobutaka Hanagata
INTERNATIONAL JOURNAL OF NANOMEDICINE (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
The role of TLR2 in infect on and immunity
Laura Oliveira-Nascimento et al.
FRONTIERS IN IMMUNOLOGY (2012)
Toll-like receptor 9 agonists as cancer therapeutics
Udo Holtick et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
Vera Hirsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines
Alenka Kuznik et al.
JOURNAL OF IMMUNOLOGY (2011)
Localisation and trafficking of Toll-like receptors: an important mode of regulation
Anne F. McGettrick et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Endogenous toll-like receptor ligands and their biological significance
Li Yu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Sara M. Mangsbo et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Youn H. Kim et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
DAMPening Inflammation by Modulating TLR Signalling
A. M. Piccinini et al.
MEDIATORS OF INFLAMMATION (2010)
A Novel Class of Immune-Stimulatory CpG Oligodeoxynucleotides Unifies High Potency in Type I Interferon Induction with Preferred Structural Properties
Ulrike Samulowitz et al.
OLIGONUCLEOTIDES (2010)
Harnessing the immune response to treat cancer
H. J. Steer et al.
ONCOGENE (2010)
Bifurcation of Toll-Like Receptor 9 Signaling by Adaptor Protein 3
Miwa Sasai et al.
SCIENCE (2010)
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
Joerg Vollmer et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Randomized Phase 2/3 Trial of CpG Oligodeoxynucleotide PF-3512676 Alone or With Dacarbazine for Patients With Unresectable Stage III and IV Melanoma
Jeffrey S. Weber et al.
CANCER (2009)
Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells
Kenji Chamoto et al.
CANCER SCIENCE (2009)
Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
John A. Thompson et al.
CLINICAL GENITOURINARY CANCER (2009)
Immunotherapy of cancer
Hossein Borghaei et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
TLR9 as a key receptor for the recognition of DNA
Yutaro Kumagai et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer
Christian Manegold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma
Maja A. Hofmann et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
A. M. Krieg
ONCOGENE (2008)
Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases
Michel Gilliet et al.
NATURE REVIEWS IMMUNOLOGY (2008)
The pharmacology of endosomal TLR agonists in viral disease
D. R. Averett et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Synthetic agonists of Toll-like receptors 7, 8 and 9
S. Agrawal et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor- mediated immune responses but not in TCR signaling
Tatsukata Kawagoe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Development of TLR9 agonists for cancer therapy
Arthur M. Krieg
JOURNAL OF CLINICAL INVESTIGATION (2007)
Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation
Marion Jurk et al.
BIODRUGS (2007)
Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma
Mikhail Pashenkov et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation
Cristiana Guiducci et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Osteopontin expression is essential for interferon-α production by plasmacytoid dendritic cells
ML Shinohara et al.
NATURE IMMUNOLOGY (2006)
Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles
Miren Kerkmann et al.
OLIGONUCLEOTIDES (2006)
Essential function for the kinase TAK1 in innate and adaptive immune responses
S Sato et al.
NATURE IMMUNOLOGY (2005)
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells
G Napolitani et al.
NATURE IMMUNOLOGY (2005)
Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft
G Pratesi et al.
CANCER RESEARCH (2005)
Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction
K Honda et al.
NATURE (2005)
IRF-7 is the master regulator of type-I interferon-dependent immune responses
K Honda et al.
NATURE (2005)
Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors
A Takaoka et al.
NATURE (2005)
Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-α induction by CpG-A in plasmacytoid dendritic cells
M Kerkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma
Xian-Song Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Immunotherapeutic uses of CpG oligodeoxynucleotides
DM Klinman
NATURE REVIEWS IMMUNOLOGY (2004)
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro
S Rothenfusser et al.
BLOOD (2004)
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
SS Diebold et al.
SCIENCE (2004)
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
F Heil et al.
SCIENCE (2004)
TLR9 signals after translocating from the ER to CpG DNA in the lysosome
E Latz et al.
NATURE IMMUNOLOGY (2004)
Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6
T Kawai et al.
NATURE IMMUNOLOGY (2004)
CpG oligodeoxynucleotide enhances tumor response to radiation
L Milas et al.
CANCER RESEARCH (2004)
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities
J Vollmer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts
A Balsari et al.
EUROPEAN JOURNAL OF CANCER (2004)
Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity
AS Lonsdorf et al.
JOURNAL OF IMMUNOLOGY (2003)
Maintenance of serological memory by polyclonal activation of human memory B cells
NL Bernasconi et al.
SCIENCE (2002)
Microanatomical localization of PD-1 in human tonsils
Y Iwaia et al.
IMMUNOLOGY LETTERS (2002)
Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA
J Jung et al.
JOURNAL OF IMMUNOLOGY (2002)
Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins
O Takeuchi et al.
JOURNAL OF IMMUNOLOGY (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
IFN-αβ promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines
HJ Cho et al.
JOURNAL OF IMMUNOLOGY (2002)
CpG are efficient Adjuvants for specific CTL induction against tumor antigen-derived peptide
I Miconnet et al.
JOURNAL OF IMMUNOLOGY (2002)
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T Okazaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
L Alexopoulou et al.
NATURE (2001)
CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved
R Rankin et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2001)
Toll-like receptors: critical proteins linking innate and acquired immunity
S Akira et al.
NATURE IMMUNOLOGY (2001)
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition
S Bauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
TAK1 is a ubiquitin-dependent kinase of MKK and IKK
C Wang et al.
NATURE (2001)
Discrimination of bacterial lipoproteins by Toll-like receptor 6
O Takeuchi et al.
INTERNATIONAL IMMUNOLOGY (2001)
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5
F Hayashi et al.
NATURE (2001)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells
TH Chuang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
A Toll-like receptor recognizes bacterial DNA
H Hemmi et al.
NATURE (2000)
Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain
L Deng et al.
CELL (2000)
The Toll receptor family and microbial recognition
R Medzhitov et al.
TRENDS IN MICROBIOLOGY (2000)
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6
H Häcker et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
The discovery of immunostimulatory DNA sequence
S Yamamoto et al.
SPRINGER SEMINARS IN IMMUNOPATHOLOGY (2000)
Mechanisms of immune stimulation by bacterial DNA
DS Pisetsky
SPRINGER SEMINARS IN IMMUNOPATHOLOGY (2000)
Share Paper
